USA-based ImmuNext has signed an agreement focused on the development of a novel antibody with the potential to treat a range of autoimmune diseases including Lupus and multiple sclerosis.
Under the terms of the accord, ImmuNext will grant French pharma major Sanofi (Euronext: SAN) an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development that suppresses the activity of a cellular pathway that is overactive in many autoimmune diseases. In addition, Sanofi and ImmuNext will initiate a research collaboration to support clinical trials.
Potential milestone payments to ImmuNext under the agreement could total $500 million. ImmuNext is also eligible to receive tiered royalties up to double digits on sales of products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze